NEW YORK – It has long been established that mutations in TP53 — the gene most frequently altered across all cancer types — can be an important predictor of patients’ survival outcomes and response to treatment.
In myeloid dysplastic syndromes, for instance, TP53 mutations are associated with shorter overall survival, resistance to standard treatments, and the transformation of MDS into acute myeloid leukemia.
Get the full story with
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.